Sponsored By
Advanced Instruments
Headline Sponsor
Advanced Instruments is a global provider of scientific and analytical solutions for the biopharma and clinical industries. Our company’s innovations have helped organizations improve quality, achieve reliable outcomes, and increase productivity for more than 70 years. Our focus on service, quality, and reliability has made us a leading developer and manufacturer of analytical instruments and services for the biopharmaceutical, clinical, and food & beverage industries. Our newest addition, the Artel portfolio, includes leading analytical instruments, software and services that validate, automate, and calibrate critical liquid handling processes and instrumentation. Our Solentim portfolio delivers best-in-class imaging and single-cell deposition technologies for cell line development workflows. And our OsmoTECH® and OsmoPRO® micro-osmometers support the workflows that labs worldwide rely on for the delivery of accurate and timely results.
Meet Our Expert Speakers
Cell Culture & Quality Control Online Symposium again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Confirmed speakers include:
Eric Wallenstein
Senior Director, Global Regulatory Affairs - CMC,
AskBio
Josh Bagley
CSO,
a:head bio AG
Paula Meleady
Associate Professor,
Dublin City University
Pedro Pinto
Lab Head Experimental Urology,
University of Greifswald
Tamara Zietek
Chief Scientific Officer,
Doctors Against Animal Experiments
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.
Feinstein Institutes Links Blood Biomarkers to Psychosis in Alzheimer's Patients
The global aging population means that rates of Alzheimer's disease are expected to reach 14 million patients by 2060, many of whom will experience psychosis.
ZERO Precision Medicine Programme Reports Outstanding Efficacy in High-Risk Paediatric Cancers
The first-of-its-kind trial presents a positive outlook for cancer types with historically poor survival rates.
Hope for New Prognostic Biomarkers & Therapeutic Options From Tumour Metabolism-Targeting Breast Cancer Study
Understanding the interplay between the tumour microenvironment and immunometabolic states could unlock a wealth of therapeutic targets and biomarkers.
New Zika-Specific Synthetic Biomarker Can Differentiate From Dengue Virus
A test that identifies Zika distinct from dengue could make a definite impact to expectant mothers and reproductive-age women that are at risk from the mosquito-borne disease.